Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-K Annual Report
Reporting Period: Fiscal year ended January 1, 2010 (52 weeks)
Business Overview: Greatbatch operates in two segments: Greatbatch Medical (components for Cardiac Rhythm Management, Neuromodulation, Vascular Access, and Orthopaedics) and Electrochem Solutions (industrial battery power and wireless sensing). The company supplies large multinational OEMs, with four customers accounting for 63% of 2009 sales.
Key Financial Metrics
| Metric | Fiscal 2009 (Ended Jan 1, 2010) | Fiscal 2008 (Ended Jan 2, 2009) |
|---|---|---|
| Total Sales | $521.8 million | $546.6 million |
| Gross Profit | $166.4 million (31.9% margin) | $155.8 million (28.5% margin) |
| Operating Income | $1.0 million (0.2% margin) | $34.9 million (6.4% margin) |
| Net Income (Loss) | ($9.0 million) | $14.1 million |
| Diluted EPS | ($0.39) | $0.62 |
| Cash Flow from Operations | $71.8 million | $57.1 million |
| Total Debt | $289.4 million | $314.4 million |
| Cash and Equivalents | $37.9 million | $22.1 million |
| Working Capital | $119.9 million | $142.2 million |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 5% year-over-year. While CRM/Neuromodulation revenue grew 7%, this was offset by declines in Orthopaedic (-20%), Vascular Access (-9%), and Electrochem (-15%) due to economic uncertainty and customer inventory adjustments.
- Significant Charges: The company recorded a $34.5 million charge related to the "Electrochem Litigation" (a jury verdict against the company) and a $15.9 million write-down of intangible assets (trademarks/tradenames) due to rebranding. These charges drove the net loss.
- Adjusted Performance: Excluding non-recurring items, Adjusted Operating Income was $62.6 million (12.0% margin), an improvement from $58.1 million (10.6% margin) in 2008.
- Debt Structure: $30.5 million of convertible notes became current liabilities due to an upcoming put option date in June 2010.
Guidance, Outlook, and Risks
- 2010 Outlook: Management expects Adjusted Operating Margin to be between 12.0% and 13.5%. Revenue growth projections for 2010 are: CRM/Neuromodulation (2-5%), Vascular Access (3-7%), Orthopaedic (3-7%), and Electrochem (0-5%).
- Litigation Risk: The company is appealing the $33 million judgment in the Electrochem Litigation. The insurer has denied coverage, and the company has accrued $34.5 million. Interest continues to accrue on the judgment during the appeal.
- Customer Concentration: Heavy reliance on four major customers (Boston Scientific, Johnson & Johnson, Medtronic, St. Jude Medical) who collectively accounted for 63% of sales in 2009.
- Regulatory & Economic Risks: Potential impacts from healthcare reform, cost containment measures, and volatility in the oil and gas industry (affecting Electrochem).
Investor Verification Checklist
- Litigation Status: Verify the current status of the Electrochem Litigation appeal and the likelihood of insurance coverage recovery.
- Customer Contracts: Confirm the renewal status of the supply agreement with Boston Scientific, which expires December 31, 2010.
- Debt Maturity: Assess the company's liquidity plan to repay the $30.5 million current portion of debt due in June 2010.
- Orthopaedic Recovery: Monitor the Orthopaedic segment for signs of recovery from the 20% revenue decline, given the expectation of persistent market challenges in the first half of 2010.
- Intangible Assets: Review the remaining $406.3 million in intangible assets (49% of total assets) for potential future impairment risks.